Publications by authors named "A H Dantzig"

Claim this Profile
E
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Susan E Pratt, Sara Durland-Busbice, Robert L Shepard, Gregory P Donoho, James J Starling, Anne H Dantzig

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Jessica A Roseberry Baker, Enaksha R Wickremsinhe, Claire H Li, Olukayode A Oluyedun, Anne H Dantzig

Drug Metab Dispos· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Susan E Pratt, Sara Durland-Busbice, Robert L Shepard, Kathleen Heinz-Taheny, Philip W Iversen, Anne H Dantzig

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Giulio Francia, Yuval Shaked, Kae Hashimoto, John Sun, Melissa Yin, Anne H Dantzig

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.
David M Bender, Jingqi Bao, Anne H Dantzig, William D Diseroad, Kevin L Law

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis